Get started
Work

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Year: 2022
Type: article
DOI: 10.1016/s2152-2650(22)00690-5
Authors: David Sallman, Monzr Al Malki, Adam Asch, Eunice Wang, Joseph Jurcic, Terrence Bradley, Ian Flinn, Daniel Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark Chao, Carol O'Hear, Indu Lal, Paresh Vyas, Naval Daver
Institutions: Moffitt Cancer Center, City Of Hope National Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, Columbia University Irving Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Tennessee Oncology, University of Colorado Anschutz, University of Colorado Denver, University of California San Diego, Moores Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, Irvine, Gilead Sciences (United States), University of Oxford, MRC Weatherall Institute of Molecular Medicine
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4296533937
FWCI: 0.364
Cites:
Cited by: 2
Related to: 10